Edition:
United States

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

117.56USD
22 Feb 2018
Change (% chg)

$-0.35 (-0.30%)
Prev Close
$117.91
Open
$118.57
Day's High
$119.65
Day's Low
$116.59
Volume
1,078,996
Avg. Vol
1,628,549
52-wk High
$125.84
52-wk Low
$61.31

Select another date:

BRIEF-Abbvie Canada Says ‍Canadians Diagnosed With Advanced Parkinson's Disease Living In Nova Scotia Now Have Public Access To Duodopa​

* ABBVIE CANADA - ‍CANADIANS DIAGNOSED WITH ADVANCED PARKINSON'S DISEASE LIVING IN NOVA SCOTIA NOW HAVE PUBLIC ACCESS TO DUODOPA​ Source text for Eikon: Further company coverage:

BRIEF-Abbvie Announces Positive Topline Results From Phase 3 Study Evaluating Investigational Elagolix In Women With Uterine Fibroids

* ABBVIE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 STUDY EVALUATING INVESTIGATIONAL ELAGOLIX IN WOMEN WITH UTERINE FIBROIDS

BRIEF-Voyager Therapeutics And Abbvie Announce Global Strategic Collaboration

* VOYAGER THERAPEUTICS AND ABBVIE ANNOUNCE GLOBAL STRATEGIC COLLABORATION TO DEVELOP POTENTIAL NEW TREATMENTS FOR ALZHEIMER’S DISEASE AND OTHER TAU-RELATED NEURODEGENERATIVE DISEASES

BRIEF-Abbvie Announces New Phase 2 Data For Upadacitinib Showing Clinical And Endoscopic Outcomes In Crohn's Disease At 52 Weeks

* ABBVIE ANNOUNCES NEW PHASE 2 DATA FOR UPADACITINIB SHOWING CLINICAL AND ENDOSCOPIC OUTCOMES IN CROHN'S DISEASE AT 52 WEEKS

AbbVie to buy back $10 billion of shares, raises dividend

AbbVie Inc said on Thursday its board had approved a $10 billion stock repurchase program, and the drugmaker also increased its quarterly dividend, as it reaped the benefits of U.S. tax law changes.

UPDATE 1-AbbVie to buy back $10 billion of shares, raises dividend

Feb 15 AbbVie Inc said on Thursday its board had approved a $10 billion stock repurchase program, and the drugmaker also increased its quarterly dividend, as it reaped the benefits of U.S. tax law changes.

AbbVie to buy back $10 billion of shares, raises dividend

Feb 15 AbbVie Inc on Thursday said its board had approved a $10 billion stock repurchase program, and the drugmaker also increased its quarterly dividend, as it reaped benefits from changes to the U.S. tax code.

BRIEF-Abbvie Increases Dividend, Announces New Stock Repurchase Program

* ABBVIE INCREASES DIVIDEND AND ANNOUNCES NEW STOCK REPURCHASE PROGRAM

BRIEF-AbbVie Receives Positive Recommendation From Canadian Drug Committee For Maviret

* ABBVIE RECEIVES A POSITIVE RECOMMENDATION FROM THE CADTH CANADIAN DRUG EXPERT COMMITTEE FOR MAVIRET™ - AN ORAL THERAPY FOR THE TREATMENT OF PATIENTS WITH HEPATITIS C Source text for Eikon: Further company coverage:

AbbVie wins U.S. trial in lawsuit over AndroGel's risks

A federal jury in Chicago on Friday found AbbVie Inc not liable in a lawsuit by an Arizona man who claimed he had suffered a pulmonary embolism due to using the company's testosterone replacement medication AndroGel.

Select another date: